Premium
Inpatient mortality of patients with multiple myeloma and renal impairment undergoing autologous stem cell transplantation
Author(s) -
Mohyuddin Ghulam Rehman,
Abbasi Saqib,
Okoniewski Maire,
McClune Brian,
Abdallah AlOla,
Ganguly Siddhartha,
McGuirk Joseph,
Shune Leyla
Publication year - 2020
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13487
Subject(s) - medicine , multiple myeloma , dialysis , autologous stem cell transplantation , melphalan , hemodialysis , peritoneal dialysis , transplantation , odds ratio , surgery
Objectives Further data are needed on the safety of high‐dose melphalan and autologous stem cell transplant (HDM‐ASCT) in patients with multiple myeloma (MM) and renal impairment. The objective of our study was to use the National Inpatient Sample (NIS) to determine inpatient mortality for patients with MM and renal impairment undergoing HDM‐ASCT, as well as trends over time. Methods Using the NIS, we tracked hospital admissions for MM patients from 2002 to 2014 who underwent HDM‐ASCT, using ICD 9 coding. Results The total weighted estimate of inpatient admissions for HDM‐ASCT among MM patients was 47,253 from 2002 to 2014. A weighted total of 45 and 1709 patients with MM received peritoneal dialysis (PD) and hemodialysis (HD) during HDM‐ASCT for MM, respectively. There was a markedly increased risk of inpatient mortality in patients on dialysis undergoing transplant (20.5% for PD patients, 13.8% for HD patients), even after accounting for other comorbidities (odds ratio of inpatient mortality of 6.193 [CI 3.585‐10.701]). A significant decrease was noted in inpatient mortality for patients with ESRD undergoing HDM‐ASCT over time from 15.6% in 2009 to 5% in 2014 ( P < .001). Conclusion Patients with MM on dialysis undergoing HDM‐ASCT are at significantly increased risk of inpatient mortality.